Screener
Castle Biosciences CSTL Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from exercise of common stock options | 322 | 18 |
| Payment of employees’ taxes on vested restricted stock units and performance-based restricted stock units | (6,598) | (2,515) |
| Proceeds from contributions to the employee stock purchase plan | 1,267 | 970 |
| Repayment of principal portion of finance lease liabilities | (24) | (26) |
| Net cash used in financing activities | (5,033) | (1,553) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (52,965) | (30,020) |
| Beginning of period | 116,729 | 119,709 |
| End of period | $63,764 | $89,689 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's net change in cash?
- Castle Biosciences (CSTL) reported net change in cash of -$52.97M in Q1 2026.
- How has Castle Biosciences's net change in cash changed year-over-year?
- Castle Biosciences's net change in cash decreased by 76.4% year-over-year, from -$30.02M to -$52.97M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Castle Biosciences's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude